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Background and purpose   Various new delivery systems for 
recombinant human bone morphogenetic protein-2 (rhBMP-2) 
have been introduced to improve its efficacy in osteogenesis. Of 
these, we have previously developed heparin-conjugated PLGA 
nanospheres (HCPN) as a long-term delivery system for BMP-2. 
In vitro studies have shown that the BMP-2 long-term delivery 
system enhances the level of bone formation. However, the long-
term effects of BMP-2 on spinal fusion have not been assessed. 
Therefore, we now tested the hypothesis that the long-term deliv-
ery of BMP-2 using HCPN improves spinal fusion compared to 
short-term delivery in a rabbit fusion model.
Methods   24 adult New Zealand White rabbits underwent pos-
terolateral fusion (6 animals in 4 groups). The autograft group 
received an autologous iliac chip bone graft as a positive control. 
The BMP-2-PN group received rhBMP-2 (20 μg per implant) and 
PLGA nanospheres (PN) suspended in fibrin gel, and served as 
a short-term release group. The HCPN group received HCPN 
suspended in fibrin gel without BMP-2 as a negative control. The 
BMP-2-HCPN group received rhBMP-2 (20 μg per implant)-
bound HCPN suspended in fibrin gel and served as a long-term 
release group. All animals were killed 12 weeks after surgery. 
Manual palpation, axial tensile tests, radiography, and histologi-
cal evaluations were then performed.
Results   The spinal fusion rate and Young’s modulus of the 
fusion mass were better in the BMP-2 long-term delivery group 
than in the short-term delivery group at an equivalent dose. How-
ever, the outcome of the long-term delivery was inferior to that of 
the autograft group. 
Interpretation   The HCPN system showed potential as an effec-
tive carrier that might improve the osteogenic efficacy of BMP-2 
for spinal fusion. 

 
 
Recent approaches to regenerate bone have used osteogenic 
growth factors in combination with carriers or scaffolds (Petite 
et al. 2000). These factors include bone morphogenic proteins 
(BMPs), basic fibroblast growth factor (bFGF), and trans-
forming growth factor-β (TGF-β) (Lieberman et al. 2002). 
However, only BMPs are capable of inducing ectopic bone 
formation in extra-osseous tissues, and are known to play a 
key role in osteoinduction. In particular, BMP-2 has been used 
as osteoinductive growth factor to promote spinal fusion to 
treat degenerative spondylosis.
BMP-2 and BMP-7 are the two BMPs that have been 
approved by the US FDA (Food and Drug Administration) 
for human use to date. The clinical equivalence of BMP-2 
in spinal fusions compared to autografts in human trials has 
been reported. Burkus et al. (2002) reported that treatment of 
patients with degenerative lumbar disc diseases with recombi-
nant human BMP-2 gave higher interbody fusion rates (95%) 
than in a control group that received autogenous iliac crest 
bone graft (89%). Another randomized human clinical study 
showed that a BMP-2-treated group showed a higher fusion 
rate (88%) than a control iliac crest bone graft group (73%) in 
posterolateral fusions (Dimar et al. 2006). In addition, similar 
results have also been reported regarding the use of BMP-7 in 
treating posteolateral lumbar arthrodesis (Vaccaro et al. 2008). 
A number of different carriers, including synthetic poly-
mers and type-I collagen, have been used to deliver BMP-2 in 
experimental and clinical studies. However, the results of such 
attempts have been less than satisfactory, so that no single car-
rier has been generally accepted as an optimal one (Minamide 
et al. 2001). Consequently, further effort to develop an opti-
mized system for delivery of BMP-2 for clinical applications 
is therefore needed.
Recent studies have shown that cell-surface or extracellular 
matrix-associated polysaccharides, including heparin, can be 
used for the sustained delivery of BMP-2 to potentiate BMP-2 
activity (Takada et al. 2003, Zhao et al. 2006). These find-
ings led to the synthesis of a heparin-conjugated poly(lactic-
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of recombinant human BMP-2 (rhBMP-2) (Jeon et al. 2007), 
which was further modified and developed as heparin-conju-
gated PLGA nanospheres (HCPNs) (Jeon et al. 2008). Based 
on the direct binding of BMP-2 to heparin, which is known 
to extend the half-life and bioactivity of BMP-2 (Zhao et al. 
2006), HCPNs suspended in fibrin gel have been reported to 
be effective in bone regeneration by facilitating the long-term 
delivery of growth factors in vivo, including BMP-2 (Jeon et 
al. 2006, 2008, La et al. 2010). 
To our knowledge, there are no data published on the effects 
on spinal fusion of the carrier-dependent release pattern of 
BMP-2. Thus, in the present study, we tested the hypothesis 
that the long-term delivery of BMP-2 using HCPN would 
improve spinal fusion compared to the short-term delivery of 
BMP-2 in a rabbit spinal fusion model. The results of the long-
term delivery of BMP-2 using HCPN were compared to those 
of the short-term delivery achieved through the use of PLGA 
nanospheres (PNs) without heparin conjugation, in addition to 
autogenous bone grafts that served as a positive control.
Material and methods
Study design
Twenty-four 12-month-old skeletally mature, healthy New 
Zealand White rabbits (KOATECH, Pyeoungtaek, Korea) 
weighing 3–3.5 kg were used. Prior to the experiments, the 
animals were allowed to adjust to their environment for 2 
weeks. They were divided into 4 groups (6 per group), based 
on the implant type. Each animal had a bilateral inter-trans-
verse process arthrodesis between the fifth and sixth lumbar 
vertebrae using a previously described protocol (Boden et al. 
1995). The autograft group received an autogenous iliac chip 
bone graft and served as a positive control. The BMP-2-PN 
group received BMP-2 and PNs suspended in fibrin gel with-
out heparin conjugation, and served as a short-term release 
group. The HCPN group received HCPNs suspended in fibrin 
gel without BMP-2 and served as a negative control. The 
BMP-2-HCPN group received BMP-2-bound HCPNs sus-
pended in fibrin gel and served as a long-term release group. 
The rabbits were maintained and cared for in accordance 
with institutional guidelines. The experimental protocol was 
approved by the Institutional Animal Care and Use Committee 
(IACUC) of Dongguk University, Goyang.
Preparation of graft materials
Recombinant human BMP-2 (produced from CHO cells) was 
purchased from R&D Systems (Minneapolis, MN). Fibrin gel 
(Greenplast) was purchased from Greencross (Seoul, Korea). 
PNs (75 mol% of lactide, MW 90,000) and HCPNs (Figure 1, 
inset image) were manufactured as described previously (Jeon 
et al. 2006). For the preparation of BMP-2-PNs and BMP-2-
HCPNs, BMP-2 (20 μg per implant) was mixed with PNs (50 
μg per implant) or HCPNs (50 μg per implant) in fibrin gel 
(2.5 mL per implant). For the HCPN group, HCPNs (50 μg 
per implant) were mixed with fibrin gel (2.5 mL per implant) 
without BMP-2. The morphological examination of HCPNs 
was performed using a scanning electron microscope.
Surgery
A posterolateral inter-transverse process arthrodesis was per-
formed in each animal bilaterally between the fifth and sixth 
lumbar vertebrae. The animals were anesthetized with an intra-
muscular injection of ketamine (35 mg/kg of body weight) 
and xylazine (8 mg/kg of body weight) under aseptic condi-
tions. Briefly, in each animal, a dorsal longitudinal incision 
was made around the spinous process. After fascia exposure, 
an incision was made using the paramedian approach. The 
intermuscular plane between the multifidus and longissimus 
muscles was developed to expose the transverse processes of 
the fifth and sixth lumbar vertebrae and the inter-transverse 
membrane bilaterally. Using a 4.0-mm electric burr, the 
exposed posterior cortex of the transverse process was decorti-
cated and the burred bone chip was irrigated. For the autograft 
group, an autogenous bone graft from the ileum was obtained 
through the same skin incision after bilateral fasciotomy on 
the posterior superior iliac spine. Prepared implants (6 bilat-
eral implants per group), iliac chip bone, BMP-2-PN, HCPN, 
and BMP-2-HCPN, were grafted between the transverse pro-
cesses in the paraspinal bed bilaterally (Figure 1). Fascial inci-
sions and the skin were sutured and gentamicin (5 mg/kg) was 
injected intramuscularly. The animals were housed individu-
ally in cages and fed rabbit chow and water ad libitum. The 
animals were monitored for general health on a daily basis. 12 
weeks after surgery, all the animals were killed by barbiturate 
overdose (100 mg/kg intraperitoneally) without damaging the 
bilateral fusion masses.
Assessment of fusion
Manual palpation. The fusion mass containing the fifth and 
the sixth lumbar vertebrae in addition to the spinous processes 
was protected from external forces during killing. To guaran-
tee a thorough examination of the union, all connective struc-
Figure 1. Left panel: Schematic illustration of spinal fusion via implants 
between the transverse processes of the fifth and lumbar vertebrae. 
Right panel: Scanning electron microscopic images of HCPN. Scale 
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tures between the vertebrae, including the anterior and poste-
rior longitudinal ligaments, the ligaments between the spinous 
processes, ligamentum flavum, facet joint membrane, and 
intervertebral disc were completely removed. Gross examina-
tion of fusion masses was performed. After the explantation, 
a manual motion test of intervertebral segments was also per-
formed. Union was defined as being when the continuity was 
maintained and the flexion and elasticity were similar to the 
bone tissue. If the fusion masses between the transverse pro-
cesses displayed flexions resembling those of soft tissue, they 
were considered to be non-unions. A partial union was defined 
as being when the results were intermediate between union 
and non-union.
Radiographic analysis. 12 weeks after the surgery, postero-
anterior radiographs were taken using a 90-cm tube-to-plate 
distance. Complete and uninterrupted radiographic bilateral 
osseous bridging of the transverse processes was considered to 
be a union. Unilateral osseous bridging or interlaminar bony 
union was considered to be a partial union, and a lack of ossi-
fication or osseous bridging was considered to be a non-union.
Mechanical testing. For mechanical testing, all remaining 
tissues around the bone masses and facet joints were removed, 
and intervertebral discs were divided with a scalpel so that 
only the fusion masses and inter-transverse membranes were 
connected to the vertebrae. Vice-type fixing tools were used 
to hold both the upper and the lower adjacent vertebral bodies 
such that the tensile force would be distributed evenly with no 
rotational stress. The fixing tools were connected to an Instron 
8500 (Instron, Norwood, MA) and tensile stress was measured 
longitudinally. The Young’s modulus of each specimen was 
calculated based on the slope of the tensile stress up to 1 cm/
cm strain. Tensile testing was performed on 12 specimens (3 
per group).
Statistics
Quantitative data were expressed as mean (SD). For the statis-
tical analysis on Young’s modulus, the one-way ANOVA test 
with Bonferroni correction was performed using OriginPro 8 
SR4 software (version 8.0951, OriginLab Corp., Northamp-
ton, MA). For the spinal union data, non-parametric Fisher’s 
exact test was performed using SAS/STAT software. Any 
p-value less than 0.05 was considered to be statistically sig-
nificant. 
Results
Manual palpation
After the surgery, 2 animals were excluded from the HCPN 
group. 1 died of unknown causes 3 weeks after surgery and the 
other was killed due to a deep infection. The remaining 22 rab-
bits tolerated the procedure well and gained weight. After en 
bloc removal, gross examination of specimens was performed. 
All specimens were blindly palpated by 2 examiners to assess 
flexion and extension at arthrodesis levels and at adjacent 
levels proximally and distally. Gross examination indicated 
that masses in the BMP-2-HCPN group were larger than those 
in the BMP-2-PN and HCPN groups. The number of animals 
showing complete union was highest in the autograft group (5 
of 6 animals), followed by the BMP-2-HCPN group (3 of 6 
animals) (Table 1). In the other 2 groups, no animals showed 
complete union. The Fisher’s exact test result indicated a cor-
relation between the type of implant and the resultant type of 
union (p = 0.009).
Radiographic analysis (Figure 2)
In the autograft and BMP-2-HCPN groups, all specimens 
showed complete bilateral bone bridge formation (6 out of 6 
animals for both groups). In the BMP-2-PN group, 2 animals 
(out of 6) showed complete bone bridge formation and the 
remaining 4 animals showed incomplete bone bridge forma-
tion or unilateral bone bridge formation. In the HCPN group, 
no complete bone bridge formation was seen (Table 2). The 
Table 1. Number of animals with different types of unions, as judged by 
manual palpation
Union type  Autograft  BMP-2-PN  HCPN  BMP-2-HCPN
Complete union  5  0  0  3
Partial union  1  5  2  3
Non-union 0  1 2  0
Total  6  6 4  6
Complete union: fusion mass continuity was maintained and flexion 
and elasticity were similar to bone tissue
Non union: fusion masses displayed flexions resembling those of soft 
tissue 
Partial union: intermediate between union and non union 
Autograft: autogenous iliac chip bone implant
BMP-2-PN: BMP-2 (20μg) mixed with PLGA nanospheres (50μg), 
suspended in fibrin gel (2.5mL)
HCPN: heparin conjugated PLGA nanospheres without BMP-2, 
suspended in fibrin gel
BMP-2-HCPN: BMP-2 mixed with heparin conjugated PLGA nano-
spheres, suspended in fibrin gel
Fisher’s exact test indicated that there was a correlation between the 
type of implant and the type of union as a result (p=0.009).
Figure 2. Representative radiographs showing the status of the spinal 
fusion between the transverse processes of the fifth and sixth lumbar 
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Fisher’s exact test result indicated that there was a significant 
correlation between the type of implant and the resultant type 
of union (p < 0.001).
Mechanical testing (Figure 3)
The Young’s modulus of the autograft groups was higher 
than in the other groups (p = 0.01, p = 0.004, and p < 0.001, 
when compared to autograft, BMP-2, and HCPN, respec-
tively) (Figure 4). Among the other groups, except the auto-
graft group, the BMP-2-HCPN had a statistically significantly 
higher Young’s modulus than the BMP-2-PN group or the 
HCPN group. 
Discussion
We found that at an equivalent dose, the HCPN-mediated 
long-term delivery of BMP-2 resulted in a higher number of 
complete spinal fusions compared to the short-term delivery 
in a rabbit model, demonstrating the importance of delivery 
systems or carriers of BMP 2 in inducing bone regeneration. 
Due to the rapid local clearance and short biological half-
life of BMP-2 (Ruhe et al. 2006), high doses of BMP-2 are 
required to induce spinal fusion, i.e. its routine clinical use 
is not cost-effective (Hsu and Wang 2008). Modification of 
carriers or delivery systems can enhance the efficacy of local 
BMP-2 delivery (Akamaru et al. 2003, Liao et al. 2003); thus, 
efforts to optimize BMP-2 delivery systems have been made 
and evaluated. We have previously reported that heparin-con-
jugated PLGA systems, including scaffolds or nanospheres, 
can prolong the release of BMP-2 at the target site (Jeon et 
al. 2007, 2008, La et al. 2010). In these delivery systems, the 
fibrin gel allows the HCPNs to be suspended so that they can 
be injected in a minimally invasive manner, and the high sur-
face-to-volume ratio of the nanospheres allows large amounts 
of BMP-2 to be loaded (Jeon et al. 2008).
In the present study, the long-term delivery of BMP-2 using 
HCPN resulted in a higher spinal fusion rate and improved 
mechanical properties compared to the short-term delivery 
or the negative control (HCPN) group. Since the only vari-
able between the BMP-2-HCPN group and the BMP-2-PN 
group was the heparin conjugation, the higher spinal fusion 
rate of the BMP-2-HCPN group appears to have been due to 
the presence of heparin in the delivery system. In this heparin-
conjugated PLGA system, BMP-2 directly binds to heparin, 
inhibiting BMP-2 degradation and prolonging the half-life 
of BMP-2 (Zhao et al. 2006). Long-term delivery of BMP-2 
using HCPN in combination with fibrin gel has been reported 
to enhance orthotopic bone formation compared to short-
term delivery (La et al. 2010). These studies indicate that the 
heparin-conjugated PLGA delivery systems release bioactive 
BMP-2 over a prolonged period of time and more efficiently 
induce bone formation.
Although the ability of BMP-2-HCPN to induce bone for-
mation was better than either BMP-2-PN or HCPN, it was 
still not as effective as the autograft. Furthermore, the fusion 
strength was higher in the autograft group than in the BMP-
2-HCPN group. A possible reason for the inferiority of the 
BMP-2-HCPN group to the autograft group may have been 
Table 2. Number of animals with different types of unions, as judged by 
radiographic examination
Union type  Autograft  BMP-2-PN  HCPN  BMP-2-HCPN
Complete  union  6 2 0 6
Partial  union  0 4 2 0
Non-union  0 0 2 0
Total  6 6 4 6
Fisher’s exact test indicated that there was a correlation between the 
type of implant and the type of union as a result (p=1.789E-04).
Figure 3. Representative stress-strain curves obtained by axial tensile 
testing. Longitudinal tensile stress of the 2 adjacent vertebral bodies 
(fifth and sixth) was measured using vice-type holders connected to a 
measuring device. 
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the low dose of BMP-2 we used. Ectopic bone formation is 
one of the most frequently reported adverse effects of using 
BMP-2 or BMP-7, and using a minimal dose of BMPs has 
been suggested as one of the possible solutions (Benglis et al. 
2008). Consequently, to minimize the possibility of ectopic 
bone formation, we used a relatively small amount of BMP-2 
(20 μg per implant) compared to that used in other previous 
studies using a similar delivery strategy. For example, a previ-
ous study showed that 3 mg of BMP-2 in combination with 
nano-hydroxyapatite/collagen/polylactic acid (nHAC/PLA) 
achieved lumbar spinal fusion comparable to that from autog-
enous iliac crest in rabbits (Liao et al. 2003). However, our 
data indicate that the dose of BMP-2 we used might be too low 
to produce comparable bone formation to that from autograft.
In summary, the number of complete spinal fusions was 
higher in the BMP-2 long-term delivery group using HCPN 
than in the short-term delivery group at an equivalent dose in 
vivo. However, probably due to the low dose of BMP-2 used 
in this study, the results of the long-term delivery group were 
inferior to those in the autograft group. Our findings suggest 
that HCPN could be a useful carrier for BMP-2 and might 
improve the osteogenic efficacy of BMP-2 for spinal fusion in 
vivo. Additional studies are required to optimize the BMP-2 
dose. 
JHP, BSK, and GII designed the study. JWL, SHL, and HSY performed the 
experiments and analyzed the data. CSK also analyzed the data. JWL and SL 
prepared the manuscript.
This work was supported by a grant (KRF-2008-313-E00356) from the 
National Research Foundation of Korea and a grant (A100443) from the 
Korea Health 21 R&D Project of the Ministry of Health, Welfare and Family 
Affairs, Republic of Korea.
No competing interests declared
 
Akamaru T, Suh D, Boden S D, Kim HS, Minamide A, Louis-Ugbo J. Simple 
carrier matrix modifications can enhance delivery of recombinant human 
bone morphogenetic protein-2 for posterolateral spine fusion. Spine. 2003; 
28 (5): 429-34.
Benglis D, Wang M Y, Levi A D. A comprehensive review of the safety profile 
of bone morphogenetic protein in spine surgery. Neurosurgery (Suppl 2) 
2008; 62 (5):ONS423-31; discussion ONS31. 
Boden S D, Schimandle J H, Hutton W C. Lumbar intertransverse-process 
spinal arthrodesis with use of a bovine bone-derived osteoinductive pro-
tein. J Bone Joint Surg (Am) 1995; 77 (9): 1404-17.
Burkus J K, Gornet M F, Dickman C A, Zdeblick T A. Anterior lumbar inter-
body fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord 
Tech 2002; 15 (5): 337-49.
Dimar J R, Glassman S D, Burkus K J, Carreon L Y. Clinical outcomes and 
fusion success at 2 years of single-level instrumented posterolateral fusions 
with recombinant human bone morphogenetic protein-2/compression 
resistant matrix versus iliac crest bone graft. Spine 2006; 31 (22): 2534-9.
Hsu W K, Wang J C. The use of bone morphogenetic protein in spine fusion. 
Spine J 2008; 8 (3): 419-25.
Jeon O, Kang S W, Lim H W, Chung J H, Kim B S. Long-term and zero-order 
release of basic fibroblast growth factor from heparin-conjugated poly(L-
lactide-co-glycolide) nanospheres and fibrin gel. Biomaterials 2006; 27 
(8): 1598-607.
Jeon O, Song S J, Kang S W, Putnam A J, Kim B S. Enhancement of ectopic 
bone formation by bone morphogenetic protein-2 released from a heparin-
conjugated poly(L-lactic-co-glycolic acid) scaffold. Biomaterials 2007; 28 
(17): 2763-71.
Jeon O, Song S J, Yang H S, Bhang S H, Kang S W, Sung M A, Lee J H, Kim 
B S. Long-term delivery enhances in vivo osteogenic efficacy of bone mor-
phogenetic protein-2 compared to short-term delivery. Biochem Bioph Res 
Comm 2008; 369 (2): 774-80.
La W G, Kang S W, Yang H S, Bhang S H, Lee S H, Park J H, Kim B S. The 
efficacy of bone morphogenetic protein-2 depends on its mode of delivery. 
Artif Organs 2010; 34 (12): 1150-3.
Liao S S, Guan K, Cui F Z, Shi S S, Sun T S. Lumbar spinal fusion with a 
mineralized collagen matrix and rhBMP-2 in a rabbit model. Spine 2003; 
28 (17): 1954-60.
Lieberman J R, Daluiski A, Einhorn T A. The role of growth factors in the 
repair of bone - Biology and clinical applications. J Bone Joint Surg  Am) 
2002; 84 (6): 1032-44.
Minamide A, Kawakami M, Hashizume H, Sakata R, Tamaki T. Evaluation 
of carriers of bone morphogenetic protein for spinal fusion. Spine 2001; 
26 (8): 933-9.
Petite H, Viateau V, Bensaid W, Meunier A, de Pollak C, Bourguignon M, 
Oudina K, Sedel L, Guillemin G. Tissue-engineered bone regeneration. Nat 
Biotechnol 2000; 18 (9): 959-63.
Ruhe P Q, Boerman O C, Russel F G M, Mikos A G, Spauwen P HM , Jansen 
J A. In vivo release of rhBMP-2 loaded porous calcium phosphate cement 
pretreated with albumin. J Mater Sci Mater Med 2006; 17 (10): 919-27.
Takada T, Katagiri T, Ifuku M, Morimura N, Kobayashi M, Hasegawa K, 
Ogamo A, Kamijo R. Sulfated polysaccharides enhance the biological 
activities of bone morphogenetic proteins. J Biol Chem 2003; 278 (44): 
43229-35.
Vaccaro A R, Whang P G, Patel T, Phillips F M, Anderson D G, Albert T J, 
Hilibrand A S, Brower R S, Kurd M F, Appannagari A, Patel M, Fischgr-
und J S. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for 
iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year 
follow-up of a pilot study. Spine J 2008;  8 (3): 457-65.
Zhao B H, Katagiri T, Toyoda H, Takada T, Yanai T, Fukuda T, Chung U I, 
Koike T, Takaoka K, Kamijo R. Heparin potentiates the in vivo ectopic 
bone formation induced by bone morphogenetic protein-2. J Biol Chem 
2006;  281 (32): 23246-53.